No interaction studies have been conducted. As with other monoclonal antibodies, the interaction potential is considered to be low.
Mepolizumab
Vedolizumab
Certolizumab pegol
Nemolizumab
Natalizumab
Belatacept
Brolucizumab
Reslizumab